YR0126
Human CCR4 Monoclonal Antibody
Size
£486.00
- SKU:
- YR0126
- Additional Names:
- CC-CKR-4|CD194|ChemR13|CKR4|CMKBR4|HGCN:14099|K5-5
- Application:
- ELISA, FuncS, Neutralisation
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- Abclonal
- Immunogen:
- Human CCR4
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- P51679
- Synonyms:
- C-C chemokine receptor type 4;C-C CKR-4;CC-CKR-4;CCR-4;CD194;chemokine (C-C motif) receptor 4;chemokine (C-C) receptor 4;ChemR13;CKR4;CMKBR4;HGCN:14099;K5-5
- Extra Details:
- Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sezary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions.Mogamulizumab selectively binds to and inhibits the activity of CCR4, which may block CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, as well as chemokine-mediated angiogenesis. Additionally, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and certain types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells. In addition to directly targeting malignant T cells expressing CCR4, mogamulizumab depletes Treg cells, an important therapeutic target in many human cancers because of their role in suppressing host antitumor immunity.
- Shipping Conditions:
- Blue Ice